# Recurrent Pleural Effusion in an Elderly Patient With Chronic Myeloid Leukemia Following Tyrosine Kinase Inhibitor Therapy

## TL;DR

An elderly patient with chronic myeloid leukemia experienced recurrent pleural effusion after tyrosine kinase inhibitor therapy, highlighting management challenges in older adults.

## Contribution

This case study emphasizes the difficulties of managing TKI-related adverse effects in elderly CML patients.

## Key findings

- An 83-year-old patient with CML developed pleural effusion after switching from dasatinib to imatinib.
- The case illustrates the impact of TKI adverse effects on elderly patients' health and treatment outcomes.

## Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative disorder treated with tyrosine kinase inhibitors (TKIs). While TKIs are effective in treating CML, their adverse effects can impact patient management. We present a case of an 83-year-old female diagnosed with CML in August 2024, initially treated with dasatinib but discontinued due to gastrointestinal toxicity. She was later started on imatinib in October 2024. One month later, she presented with progressive weakness and dyspnea, ultimately found to have a large pleural effusion requiring intervention. This case highlights the challenges in managing TKI-related adverse effects, particularly in elderly patients.